Forty-one percent of subjects (97/235) had nondetectable plasma HCV-RNA levels at Week 4 and Week 24 of therapy.
Neljakümne ühel protsendil patsientidest (97/ 235) oli HCV- RNA 4- ndal ja 24- ndal ravinädalal allpool määramispiiri.